Answers are grounded in this paper and cite their sources.
Phase III trials and their open-label extensions have established the efficacy of tildrakizumab in moderate-to-severe plaque psoriasis, but real-world evidence beyond 3 years of treatment is lacking. We assessed the long-term effectiveness, drug survival, and safety of tildrakizumab in routine clinical practice up to 5 years of follow-up. A total of 1354 adult patients with moderate-to-severe psoriasis, treated with tildrakizumab for at least 16 weeks, were enrolled across 17 Italian Dermatology Units. Effectiveness was assessed as the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 90, PASI 100, and absolute PASI ≤ 2 between week 16 and year 5. Drug survival was estimated by the Kaplan–Meier method, and multivariable logistic regression was used to identify baseline predictors of complete skin clearance. After 1 year of treatment, PASI 90, PASI 100, and PASI ≤ 2 were achieved by 74.0%, 57.2%, and 90.6% of patients, respectively, and responses were maintained through year 5 (87.3%, 76.2%, and 93.7%) in the 63 patients evaluable as observed. Overall drug survival was 92.0% at year 1 and 78.2% at year 5. A short disease duration was the only independent predictor of PASI 100, whereas obesity and cardiometabolic comorbidities did not impair response. No new safety signals emerged. In this 5-year real-world analysis, tildrakizumab maintained deep responses and high persistence across comorbid and difficult-to-treat subgroups, while short disease duration independently predicted complete clearance.
No takes yet. Share an insight, caveat, or question.
Valenti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: